DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
drugmaker Sandoz - 1 We've - 1 it'll - 1 Prem Shah - 1 drugmaker - 1 Amgen's Amjevita - 1 Murdo Gordon - 1 Abbvie - 1
Top related locs:
U.S Red California
Top related orgs:
CVS Health - 1 CVS - 1 Cardinal Health - 1 Novartis Pharmaceuticals - 1 Sandoz - 1 Novartis - 1 FDA - 1 Blue - 1

Search resuls for: "Novartis Pharmaceuticals"


3 mentions found


☆ CVS pushes into making cheaper versions of complex drugs with new discount Humira
  + stars: | 2023-08-23 | by ( Bertha Coombs | ) www.cnbc.com   time to read: +4 min
CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira that will sell for 80% below the price of the brand-named drug. The move is part of the company's new venture focused on securing, and in some cases co-producing, biosimilar drugs, which are the equivalent of generic versions of complex gene or protein-based therapies known as biologics. CVS is already one of the leading players when it comes to sourcing generic drugs through Red Oak, its joint venture with Cardinal Health . Abbvie reported more than $4 billion in Humira sales in its most recent quarter, which was slightly better than expected. Correction: CVS Health subsidiary Cordavis will partner with Sandoz on biosimilar drugs.
Persons: drugmaker Sandoz, We've, it'll, Prem Shah, drugmaker, Amgen's Amjevita, Murdo Gordon, Abbvie, Cuban's, John Ransom, Raymond James, Ransom, Sandoz Organizations: CVS Health, CVS, Cardinal Health, Novartis Pharmaceuticals, Sandoz, Novartis, FDA, Blue, Drug Company, Amazon Pharmacy Locations: U.S, Red, California
☆ US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent
  + stars: | 2023-04-17 | by ( Blake Brittain | Thomson Reuters | Blake Brittain Reports On Intellectual Property Law | ) www.reuters.com   time to read: +2 min
REUTERS/Brian Snyder/File PhotoWASHINGTON, April 17 (Reuters) - The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp's (NOVN.S) bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China's HEC Pharm Co Ltd (1558.HK). Novartis sued HEC and more than a dozen other generic drugmakers for patent infringement in Delaware federal court after they applied for FDA approval of Gilenya generics. Novartis settled with some of the drugmakers, allowing for some Gilenya generics before a key patent's 2027 expiration. The Supreme Court in October rejected a Novartis emergency bid to pause the decision. HEC responded that the Federal Circuit "followed its own rules," and that "no Federal Circuit judge - including the dissenter - suggested any procedural concern" with the decision.
☆ U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug
  + stars: | 2022-10-13 | by ( Boies | Hausfeld Among Law Firms Reaping | Mln Windfall In Blue Cross Antitrust Case | ) www.reuters.com   time to read: 1 min
Oct 13 (Reuters) - The U.S. Supreme Court on Thursday turned down Novartis Pharmaceuticals Corp's (NOVN.S) bid to block the launch of generic versions of the company's blockbuster multiple sclerosis drug Gilenya in a dispute with China's HEC Pharm Co Ltd (1558.HK) and other generic drugmakers. Novartis had asked the justices to stay a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales. Register now for FREE unlimited access to Reuters.com RegisterReporting by Nate Raymond in Boston Editing by Chris ReeseOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 3